Haemonetics Corporation (NYSE: HAE) announced it intends to publish its second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The company will host a conference call with investors and analysts to discuss these results and answer questions later that morning.

The investor call is scheduled for 8:00 am ET on November 5, 2026. Participants can access the call via teleconference after completing registration, which provides a dial-in number and personalized PIN. Haemonetics recommends joining the line 10 minutes prior to the event start time.

Access and Replay Details

A live webcast of the conference call will be available on the company's investor relations website. For those unable to attend live, a replay of both the conference call and webcast will be accessible for one year beginning at 11:00 am ET on November 5, 2026.

About Haemonetics

Haemonetics is a global medical technology company focused on improving the quality, effectiveness, and efficiency of healthcare. Its operations are divided into two primary segments:

• Apheresis: Features proprietary technologies designed to enhance safety, yield, donor satisfaction, and operational efficiency for plasma and blood collectors worldwide.
• MedSurg: Offers Blood Management Technologies to inform treatment decisions and optimize blood product management, alongside Interventional Technologies including advanced vascular closure systems and sensor-guided technologies.

Haemonetics Corp (NYSE: HAE) shares reached a new 52-week high on Tuesday afternoon after the Boston-based medical technology provider announced a significant commercial agreement with CSL Plasma Inc.

The company disclosed that it has executed a non-exclusive supply agreement with CSL Plasma, enabling the plasma collection firm to adopt Haemonetics’ NexSys PCS devices equipped with Persona PLUS technology across its U.S. network. Under the terms finalized on Aug. 14, CSL Plasma may utilize these advanced devices and purchase related single-use disposables at its domestic collection centers.

Deal Structure and Financial Impact

The arrangement operates without any minimum purchase commitments, providing flexibility for both parties as they navigate the integration process. Haemonetics anticipates that CSL will gradually transition a portion of its U.S. locations to the platform, though the specific scope and implementation schedule remain undetermined.

Due to this uncertainty regarding the rollout timeline and volume, Haemonetics stated it is not updating its previously issued guidance for fiscal 2027. Management noted in an SEC filing that it expects to provide a clearer update on the anticipated financial impact during its second fiscal quarter earnings call in November 2026.

Market Reaction

Investors responded positively to the news, driving the stock higher throughout the trading session.

Following the announcement, BTIG analyst Marie Thibault reiterated a Buy rating on Haemonetics shares and raised the firm’s price target from $96 to $110.

What the Numbers Show

The sharp 16.01% price surge to $104.72 indicates strong market confidence in the long-term revenue potential of the CSL Plasma partnership, despite the absence of immediate minimum purchase guarantees. The upward revision of the price target by BTIG further underscores analyst belief that the deal represents a material growth driver for Haemonetics’ top-line in the coming fiscal years.